All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
7E09091

IPODD?IBD: proteases offer new targets for drug discovery

Public support

  • Provider

    Ministry of Education, Youth and Sports

  • Programme

  • Call for proposals

    FP7-HEALTH-2007-A

  • Main participants

  • Contest type

    RP - Co-financing of EC programme

  • Contract ID

    3098/2010-32

Alternative language

  • Project name in Czech

    IPODD?IBD: proteases offer new targets for drug discovery

  • Annotation in Czech

    The inflammatory bowel diseases (IBD) which comprise Crohn?s disease and ulcerative colitis are chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract. The frequency of these conditions has increased in recent decades, particularly in countries making the transition from developing to developed nation status. In western Europe, IBD now affects between 1/1000 and 5/1000 of the population, and the prevalence of the conditions in new EU accession countries appears to be growing as they develop. Few conditions in all of clinical medicine are linked with as much morbidity and potential mortality as IBD. Current treatment is based upon steroid therapy or neutralizing the effect of pro-inflammatory cytokines, especially TNFalpha.Despite their efficacy, many patients eventually require surgery for refractory disease or complications (stricture, perforation, abscess). In response to the call we have assembled a multidisciplinary team of international experts to delineate the roleof intestinal proteases and their inhibitors in the pathophysiology of IBD. A particularly innovative aspect of our approach is the examination of both bacterial and host derived proteases and interactions between the two. The ultimate aim is develop novel therapeutics and increased understanding of the disease both of which will impact within the wider EU community and globally.

Scientific branches

  • R&D category

    ZV - Basic research

  • CEP classification - main branch

    EC - Immunology

  • CEP - secondary branch

    EE - Microbiology, virology

  • CEP - another secondary branch

    EB - Genetics and molecular biology

  • OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

    10603 - Genetics and heredity (medical genetics to be 3)<br>10604 - Reproductive biology (medical aspects to be 3)<br>10605 - Developmental biology<br>10606 - Microbiology<br>10607 - Virology<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>30101 - Human genetics<br>30102 - Immunology

Completed project evaluation

  • Provider evaluation

    U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

  • Project results evaluation

    Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider.

Solution timeline

  • Realization period - beginning

    Nov 1, 2009

  • Realization period - end

    May 31, 2011

  • Project status

    U - Finished project

  • Latest support payment

    Apr 20, 2011

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP12-MSM-7E-U/01:1

  • Data delivery date

    Jul 12, 2012

Finance

  • Total approved costs

    756 thou. CZK

  • Public financial support

    756 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    0 thou. CZK